new warnings for patients taking Cylert (pemoline)

July 1999

You'll see new warnings for patients taking Cylert (pemoline).

Cylert is no longer recommended for initial therapy of attention deficit disorder (ADD)...due to the risk of liver toxicity.

Now Abbott recommends that patients sign a consent form before starting Cylert...and get liver function tests EVERY TWO WEEKS.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

new med for type 2 diabetes, Avandia (rosiglitazone)
Infectious Diseases restricting the use of Trovan (trovafloxacin)
Gastroenterology warning patients not to drink grapefruit juice while taking Propulsid (cisapride)
Women's Health LOWER doses of estrogen to prevent osteoporosis
Women's Health Many women are afraid that estrogen replacement therapy increases the risk of breast cancer
Women's Health tamoxifen and raloxifene for preventing breast cancer
now Pygeum africanum is the latest herb that's being promoted for benign prostatic hyperplasia
"andro" supplements DON'T build muscle
Antidepressants are gaining more acceptance for treating anxiety disorders
Wellbutrin SR for weight loss
new warnings for patients taking Cylert (pemoline)
Dermatology The FDA will no longer allow sunscreens to claim specific SPFs over 30
Dermatology using cimetidine (Tagamet, etc) for warts
Restless Legs new treatments for Restless Legs Syndrome (RLS)
Bipolar Disorder Neurontin (gabapentin) and Lamictal (lamotrigine) may be useful for treating bipolar disorder
Bipolar Disorder omega-3 fatty acids for bipolar disorder
possible interaction between Celebrex (celecoxib) and warfarin
Practice no longer market Hismanal (astemizole)